Last updated on November 2017

A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)


Brief description of study

A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)

Detailed Study Description

The primary purpose of this study is to demonstrate improvements in lung function for subjects treated with UMEC/VI compared with UMEC for 24 weeks. The effect of UMC/VI, UMEC, and salmeterol with respect to patient HRQoL measured through patient reported outcomes (PROs) Questionnaires, symptoms and lung function will also be evaluated

Clinical Study Identifier: TX82335

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kathleen McNulty, MHS, CCRC

The Lung Research Center
Chesterfield, MO USA
  Connect »